| 70.42 1.73 (2.52%) | 04-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 84.15 | 1-year : | 98.29 |
| Resists | First : | 72.05 | Second : | 84.15 |
| Pivot price | 68.05  |
|||
| Supports | First : | 65.91 |
Second : | 62.13 |
| MAs | MA(5) : | 70.16 |
MA(20) : | 67.71 |
| MA(100) : | 72.8  |
MA(250) : | 61.64 |
|
| MACD | MACD : | 0.5 |
Signal : | 0 |
| %K %D | K(14,3) : | 74.3 |
D(3) : | 80.1 |
| RSI | RSI(14): 56.4 |
|||
| 52-week | High : | 87.5 | Low : | 35.95 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PTCT ] has closed below upper band by 19.1%. Bollinger Bands are 8.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 70.71 - 71.05 | 71.05 - 71.41 |
| Low: | 67.54 - 67.9 | 67.9 - 68.26 |
| Close: | 69.84 - 70.41 | 70.41 - 71 |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Mon, 13 Apr 2026
Is It Time To Reassess PTC Therapeutics (PTCT) After Its Strong One Year Rally? - Sahm
Sun, 12 Apr 2026
PTCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Sun, 12 Apr 2026
B of A Securities Lowers Price Target for PTC Therapeutics (PTCT) to $93 | PTCT Stock News - GuruFocus
Sat, 11 Apr 2026
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Upgraded by Raymond James Financial - MarketBeat
Fri, 10 Apr 2026
PTC Therapeutics (NASDAQ:PTCT) Now Covered by Analysts at Raymond James Financial - MarketBeat
Wed, 08 Apr 2026
PTC Therapeutics (PTCT) EVP trades options and sells 2,265 shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 83 (M) |
| Shares Float | 73 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 113.4 (%) |
| Shares Short | 8,850 (K) |
| Shares Short P.Month | 9,590 (K) |
| EPS | 8.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.52 |
| Profit Margin | 39.4 % |
| Operating Margin | -49.6 % |
| Return on Assets (ttm) | 23.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -22.8 % |
| Gross Profit (p.s.) | 14.86 |
| Sales Per Share | 20.9 |
| EBITDA (p.s.) | 10.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 711 (M) |
| Levered Free Cash Flow | 212 (M) |
| PE Ratio | 8.2 |
| PEG Ratio | 0 |
| Price to Book value | -27.95 |
| Price to Sales | 3.36 |
| Price to Cash Flow | 8.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|